Novel antigen design for the generation of antibodies to G-protein-coupled receptors

被引:3
|
作者
Larsson, K. [1 ]
Hofstrom, C. [2 ]
Lindskog, C. [3 ]
Hansson, M. [4 ]
Angelidou, P. [4 ]
Hokfelt, T. [5 ]
Uhlen, M. [1 ]
Wernerus, H. [4 ]
Graslund, T. [2 ]
Hober, S. [1 ]
机构
[1] KTH AlbaNova Univ Ctr, Sch Biotechnol, Div Prote, Stockholm, Sweden
[2] KTH AlbaNova Univ Ctr, Sch Biotechnol, Div Mol Biotechnol, Stockholm, Sweden
[3] Uppsala Univ, Rudbeck Lab, Dept Genet & Pathol, Uppsala, Sweden
[4] AlbaNova Univ Ctr, Atlas Antibodies, Stockholm, Sweden
[5] Karolinska Inst, Dept Neurosci, Stockholm, Sweden
基金
瑞典研究理事会;
关键词
GPCR; Antibody; Antigen design; EXPRESSION; PROTEOMICS; SELECTIVITY; VALIDATION; PRODUCTS; GENOMICS; ATLAS;
D O I
10.1016/j.jim.2011.05.001
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Antibodies are important tools for the study of G-protein-coupled receptors, key proteins in cellular signaling. Due to their large hydrophobic membrane spanning regions and often very short loops exposed on the surface of the cells, generation of antibodies able to recognize the receptors in the endogenous environment has been difficult. Here, we describe an antigen-design method where the extracellular loops and N-terminus are combined to a single antigen for generation of antibodies specific to three selected GPCRs: NPY5R, B2ARN and GLP1R. The design strategy enabled straightforward antigen production and antibody generation. Binding of the antibodies to intact receptors was analyzed using flow cytometry and immunofluorescence based confocal microscopy on A-431 cells overexpressing the respective GPCR. The antibody-antigen interactions were characterized using epitope mapping, and the antibodies were applied in immunohistochemical staining of human tissues. Most of the antibodies showed specific binding to their respective overexpressing cell line but not to the non-transfected cells, thus indicating binding to their respective target receptor. The epitope mapping showed that sub-populations within the purified antibody pool recognized different regions of the antigen. Hence, the genetic combination of several different epitopes enables efficient generation of specific antibodies with potential use in several applications for the study of endogenous receptors. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:14 / 23
页数:10
相关论文
共 50 条
  • [1] Characterisation of G-protein-coupled receptors by antibodies
    Eckard, CP
    Beck-Sickinger, AG
    CURRENT MEDICINAL CHEMISTRY, 2000, 7 (09) : 897 - 910
  • [2] Novel human G-protein-coupled receptors
    Vanti, WB
    Nguyen, T
    Cheng, R
    Lynch, KR
    George, SR
    O'Dowd, BF
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 305 (01) : 67 - 71
  • [3] G-protein-coupled receptors
    Bergsma, DJ
    Wilson, S
    BIOFUTUR, 1999, (191) : 26 - 27
  • [4] Engineering therapeutic antibodies targeting G-protein-coupled receptors
    Jo, Migyeong
    Jung, Sang Taek
    EXPERIMENTAL AND MOLECULAR MEDICINE, 2016, 48 : e207 - e207
  • [5] Modelling G-protein-coupled receptors for drug design
    Flower, DR
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON BIOMEMBRANES, 1999, 1422 (03): : 207 - 234
  • [6] Opportunities for therapeutic antibodies directed at G-protein-coupled receptors
    Catherine J. Hutchings
    Markus Koglin
    William C. Olson
    Fiona H. Marshall
    Nature Reviews Drug Discovery, 2017, 16 : 787 - 810
  • [7] Opportunities for therapeutic antibodies directed at G-protein-coupled receptors
    Hutchings, Catherine J.
    Koglin, Markus
    Olson, William C.
    Marshall, Fiona H.
    NATURE REVIEWS DRUG DISCOVERY, 2017, 16 (11) : 787 - +
  • [8] DESIGN OF A DISCRIMINATING FINGERPRINT FOR G-PROTEIN-COUPLED RECEPTORS
    ATTWOOD, TK
    FINDLAY, JBC
    PROTEIN ENGINEERING, 1993, 6 (02): : 167 - 176
  • [9] G-PROTEIN-COUPLED RECEPTORS A novel double act
    Harrison, Charlotte
    NATURE REVIEWS DRUG DISCOVERY, 2008, 7 (12) : 976 - 977
  • [10] Genetic variation in G-protein-coupled receptors - consequences for G-protein-coupled receptors as drug targets
    Tang, CM
    Insel, PA
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2005, 9 (06) : 1247 - 1265